Every 10-Q that Voyager Therapeutics, Inc. (VYGR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VYGR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VYGR filings page.
Voyager Therapeutics, Inc., a neurology‑focused biotechnology company, reported collaboration revenue of $3.2 million for the quarter ended June 30, 2026, compared with $5.2 million a year earlier. Lower research and development and general and administrative spending reduced the quarterly net loss to $24.5 million from $33.4 million.
As of June 30, 2026, cash, cash equivalents and marketable securities totaled $148.8 million, with total assets of $197.8 million and stockholders’ equity of $154.4 million. The company expects this liquidity to cover planned operating and capital needs for at least twelve months.
Voyager highlights progress in its Alzheimer’s pipeline. VY1706, a tau‑silencing gene therapy, received FDA Investigational New Drug clearance in the second quarter of 2026 and a Health Canada Clinical Trial Application clearance in July 2026, with first dosing in an early Alzheimer’s trial expected in the fourth quarter of 2026 and initial safety data anticipated in early 2027. VY7523, an anti‑tau antibody, is in a Phase 1 multiple‑ascending‑dose study in early Alzheimer’s patients, with initial tau PET imaging efficacy data expected in the fourth quarter of 2026. Multiple CNS gene‑therapy collaborations with Neurocrine, Novartis, Alexion and Transition Bio have provided over $500 million in non‑dilutive funding and could yield up to $6.8 billion in future milestones plus royalties.
Voyager Therapeutics, Inc. reported a net loss of $27.9 million for the three months ended March 31, 2026, slightly improved from $31.0 million a year earlier. Collaboration revenue was $2.6 million, down from $6.5 million, mainly from Neurocrine and Novartis agreements.
Research and development expense fell to $24.6 million from $31.5 million as the company reprioritized its pipeline, including lower spend on discontinued and completed programs while ramping its tau gene therapy candidate VY1706. General and administrative costs declined to $8.3 million.
Cash, cash equivalents, and marketable securities totaled $171.7 million as of March 31, 2026, and management currently expects this, along with collaboration reimbursements and interest income, to fund planned operations into 2028. The company had 60.4 million common shares outstanding as of April 30, 2026.
Voyager Therapeutics reported Q3 2025 results showing lower collaboration revenue and a wider loss as it advances its neurology pipeline. Collaboration revenue was $13.4 million versus $24.6 million a year ago, while operating expenses rose to $44.0 million from $38.4 million, driving a net loss of $27.9 million compared with $9.0 million in Q3 2024. For the first nine months, collaboration revenue was $25.0 million versus $73.7 million a year earlier, with a net loss of $92.3 million.
Cash, cash equivalents, and marketable securities totaled $229.0 million as of September 30, 2025, and management expects this to fund operations for at least 12 months. The company continues to invest in Alzheimer’s programs VY7523 (anti‑tau antibody, Phase 1 MAD started in early AD) and VY1706 (tau‑silencing gene therapy, IND planned in 2026). A subsequent event notes Novartis’ partial termination of a 2022 option and license agreement for two programs effective February 1, 2026; one Novartis program remains under that agreement.